| Title |
Durable Antibody Responses Following One Dose of the Bivalent Human Papillomavirus L1 Virus-Like Particle Vaccine in the Costa Rica Vaccine Trial
|
|---|---|
| Published in |
Cancer Prevention Research, November 2013
|
| DOI | 10.1158/1940-6207.capr-13-0203 |
| Pubmed ID | |
| Authors |
Mahboobeh Safaeian, Carolina Porras, Yuanji Pan, Aimee Kreimer, John T. Schiller, Paula Gonzalez, Douglas R. Lowy, Sholom Wacholder, Mark Schiffman, Ana C. Rodriguez, Rolando Herrero, Troy Kemp, Gloriana Shelton, Wim Quint, Leen-Jan van Doorn, Allan Hildesheim, Ligia A. Pinto |
| Abstract |
The Costa Rica HPV16/18 Vaccine Trial (CVT) showed that four-year vaccine efficacy against 12-month HPV16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle (VLP) vaccine. Live-attenuated viral vaccines, but not simple-subunit vaccines, usually induce durable lifelong antibody responses after a single dose. It is unclear whether noninfectious VLP vaccines behave more like live-virus or simple-subunit vaccines in this regard. To explore the likelihood that efficacy will persist longer term, we investigated the magnitude and durability of antibodies to this vaccine by measuring HPV16- and HPV18-specific antibodies by VLP-ELISA using serum from enrollment, vaccination, and annual visits through four years in four vaccinated groups; one-dose (n = 78), two-doses separated by one month (n = 140), two doses separated by six months (n = 52), and three scheduled doses (n = 120, randomly selected). We also tested enrollment sera from n = 113 HPV16- or HPV18 L1-seropositive women prevaccination, presumably from natural infection. At four years, 100% of women in all groups remained HPV16/18 seropositive; both HPV16/18 geometric mean titers (GMT) among the extended two-dose group were non-inferior to the three-dose group, and ELISA titers were highly correlated with neutralization titers in all groups. Compared with the natural infection group, HPV16/18 GMTs were, respectively, at least 24 and 14 times higher among the two-dose and 9 and 5 times higher among one-dose vaccinees. Antibody levels following one-dose remained stable from month 6 through month 48. Results raise the possibility that even a single dose of HPV VLPs will induce long-term protection. |
X Demographics
The data shown below were collected from the profiles of 301 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 56 | 19% |
| Brazil | 53 | 18% |
| United Kingdom | 9 | 3% |
| Ecuador | 4 | 1% |
| Mexico | 3 | <1% |
| Spain | 3 | <1% |
| Ireland | 3 | <1% |
| Japan | 2 | <1% |
| Colombia | 2 | <1% |
| Other | 26 | 9% |
| Unknown | 140 | 47% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 256 | 85% |
| Scientists | 36 | 12% |
| Science communicators (journalists, bloggers, editors) | 6 | 2% |
| Practitioners (doctors, other healthcare professionals) | 3 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| United Kingdom | 1 | <1% |
| Spain | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 139 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 15% |
| Student > Ph. D. Student | 16 | 11% |
| Student > Master | 15 | 10% |
| Other | 14 | 10% |
| Student > Doctoral Student | 14 | 10% |
| Other | 34 | 24% |
| Unknown | 30 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 35% |
| Agricultural and Biological Sciences | 16 | 11% |
| Biochemistry, Genetics and Molecular Biology | 14 | 10% |
| Immunology and Microbiology | 9 | 6% |
| Nursing and Health Professions | 4 | 3% |
| Other | 17 | 12% |
| Unknown | 34 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 404. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 June 2023.
All research outputs
#75,095
of 25,736,439 outputs
Outputs from Cancer Prevention Research
#6
of 1,458 outputs
Outputs of similar age
#493
of 228,284 outputs
Outputs of similar age from Cancer Prevention Research
#1
of 24 outputs
Altmetric has tracked 25,736,439 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,458 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,284 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.